Table 5.
Joint effects analysis of CDK1 and CDK4 expression in HCC patients
| Group | CDK1 | CDK4 | Patient | OS | |||||
|---|---|---|---|---|---|---|---|---|---|
| No. of events | MST | HR (95% CI) | P | Adjusted HRa (95% CI) | Adjusted Pa | ||||
| TCGA | (n = 370) | days | |||||||
| A | High | High | 135 | 56 | 899 | 1 | 1 | ||
| B | High | Low | 50 | 21 | 1490 | 0.769 (0.465–1.271) | 0.305 | 0.704 (0.408–1.216) | 0.209 |
| C | Low | High | 50 | 20 | 1622 | 0.760 (0.455–1.269) | 0.294 | 0.857 (0.489–1.502) | 0.591 |
| D | Low | Low | 135 | 33 | 2456 | 0.430 (0.279–0.662) | < 0.001 | 0.491 (0.307–0.785) | 0.003 |
| GSE14520 | (n = 212) | months | |||||||
| a | High | High | 80 | 37 | 57.9 | 1 | 1 | ||
| b | High | Low | 2 | 12 | 52.7 | 0.989 (0.515–1.897) | 0.972 | 1.170 (0.606–2.258) | 0.641 |
| c | Low | High | 26 | 10 | NA | 0.756 (0.376–1.522) | 0.434 | 0.566 (0.273–1.173) | 0.126 |
| d | Low | Low | 80 | 23 | NA | 0.480 (0.285–0.808) | 0.006 | 0.431 (0.255–0.729) | 0.002 |
OS, overall survival; MST, median survival time; HR, hazard ratio; CI, confidence interval; NA, not available
aAdjusted for tumor size, cirrhosis, BCLC stage in GSE14520 cohort; and adjusted for tumor stage and radical resection in TCGA cohort